A norovirus vaccine on the horizon?

Journal of Infectious Diseases

Volumn 202, Issue 11, 2010, Pages 1623-1625

  Vinjé, Jan ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B VACCINE; NOROVIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE; WART VIRUS VACCINE;

CLINICAL TRIAL; DISEASE TRANSMISSION; EDITORIAL; EPIDEMIC; GASTROENTERITIS; HUMAN; IMMUNE RESPONSE; INFECTION RESISTANCE; INFECTION RISK; MUCOSAL IMMUNITY; NONHUMAN; NOROVIRUS; PRIORITY JOURNAL; VIRUS LIKE AGENT;

ADMINISTRATION, INTRANASAL; CALICIVIRIDAE INFECTIONS; CLINICAL TRIALS, PHASE II AS TOPIC; GASTROENTERITIS; HUMANS; NOROVIRUS; VIRAL VACCINES;

EID: 78649626995     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/657088     Document Type: Editorial

References (22)

1. Widdowson MA, Sulka A, Bulens SN, et al. Norovirus and foodborne disease, United States, 1991-2000. Emerg Infect Dis 2005; 11(1):95-102.
2. Centers for Disease Control and Prevention (CDC). Surveillance for foodborne disease outbreaks - United States, 2006. MMWR Morb Mortal Wkly Rep 2009; 58(22):609-615.
3. Verhoef L, Vennema H, van Pelt W, et al. Food-borne viruses in Europe network: use of norovirus genotype profiles to differentiate origins of foodborne outbreaks. Emerg Infect Dis 2010; 16(4):617-624.
4. Glass RI, Parashar UD, Estes MK. Norovirus gastroenteritis. N Engl J Med 2009; 361:1776-1778.
5. Siebenga JJ, Vennema H, Renckens B, et al. Epochal evolution of GGII.4 norovirus capsid proteins from 1995 to 2006. J Virol 2007; 81(18):9932-9941.
6. Duizer E, Schwab KJ, Neill FH, Atmar RL, Koopmans MP, Estes MK. Laboratory efforts to cultivate noroviruses. J Gen Virol 2004; 85:79-87.
7. Parrino TA, Schreiber DS, Trier JS, Kapikian AZ, Blacklow NR. 1977 Clinical immunity in acute gastroenteritis by the Norwalk agent. N Engl J Med 1977; 297:86-89.
8. Wyatt RG, Dolin R, Blacklow NR, et al. Comparison of three agents of acute infectious nonbacterial gastroenteritis by cross-challenge in volunteers. J Infect Dis 1974; 129:709-714.
9. Hutson AM, Atmar RL, Graham DY, Estes MK. Norwalk virus infection and disease is associated with ABO histo-blood group type. J Infect Dis 2002; 185(9):1335-1337.
10. Lindesmith L, Moe C, Marionneau S, et al. Human susceptibility and resistance to Norwalk virus infection. Nat Med 2003; 9(5):548-553.
11. Deng H, Liu R, Ellmeier W, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996; 381(6584):661-666.
12. Paxton WA, Kang S. Chemokine receptor allelic polymorphisms: relationships to HIV resistance and disease progression. Semin Immunol 1998; 10(3):187-194.
13. Santi L, Huang Z, Mason H. Virus-like particles production in green plants. Methods 2006; 40(1):66-76.
14. Herbst-Kralovetz M, Mason HS, Chen Q. Norwalk virus-like particles as vaccines. Expert Rev Vaccines 2010; 9(3):299-307.
15. Pulendran B, Ahmed R. Translating innate immunity into immunological memory: implications for vaccine development. Cell 2006; 124(4):849-863.
16. Periwal SB, Kourie KR, Ramachandaran N, et al. A modified cholera holotoxin CT-E29H enhances systemic and mucosal immune responses to recombinant Norwalk virus-virus like particle vaccine. Vaccine 2003; 21(5):376-385.
17. Holmgren J, Adamsson J, Anjuère F, et al. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Immunol Lett 2005; 97(2):181-188.
18. El-Kamary SS, Pasetti MF, Mendelman PM, et al. Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues. J Infect Dis 2010; 201(11):1649-1658 (in this issue).
19. Ball JM, Graham DY, Opekun AR, Gilger MA, Guerrero RA, Estes MK. Recombinant Norwalk virus-like particles given orally to volunteers: phase I study. Gastroenterology 1999; 117:40-48.
20. Tacket CO, Sztein MB, Losonsky GA, Wasserman SS, Estes MK. Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers. Clin Immunol 2003; 108(3):241-247.
21. Illum L, Jabbal-Gill I, Hinchcliffe M, Fisher AN, Davis SS. Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev 2001; 51(1):81-96.
22. Reeck A, Kavanagh O, Estes MK, et al. Serological correlative of protection against norovirus-induced gastroenteritis. J Infect Dis 2010; 202(8):1212-1218.